Browse studies

Find your next paid study

18 recruiting studies matching your filters

Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have ha…

Multiple Myeloma, Newly DiagnosedMultiple Myeloma (MM)

Estimated

~$10 – $8,750

SCRI Development Innovations, LLCNCT06974786

Phase 1

A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma

Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem ce…

Newly Diagnosed Glioblastoma

Estimated

~$10 – $6,250

Swedish Medical CenterNCT05380349

Phase 2

A Phase 2 Randomized Open-Label Pilot Study of Granulocyte Colony Stimulating Factor (G-CSF) to Preserve Brain Structure and Function Following Standard Chemoradiation in Patients With Newly Diagnosed MGMT-Methylated Glioblastoma

This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are…

MGMT-Methylated GlioblastomaGlioblastoma (GBM)Newly Diagnosed Glioblastoma Multiforme

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06649851

Observational

Improving Breast Cancer Patients' Self-Efficacy and Sexual Health Quality of Life

Approximately 200 English- or Spanish-speaking women newly diagnosed with stage I-III breast cancer will be randomized to either receive access to an online se…

Breast Cancer FemalesNewly Diagnosed Breast Cancer

Estimated

~$10 – $6,250

University of Colorado, DenverNCT07434817

Phase 3

A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status…

Multiple MyelomaNewly Diagnosed Multiple Myeloma

Estimated

~$10 – $7,500

GlaxoSmithKlineNCT06679101

Phase 1

Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-V11

The purpose of this research study is to determine the safety and efficacy of administering a single intracerebral (within the brain) dose of investigational c…

Newly Diagnosed MGMT Unmethylated Glioblastoma

Estimated

~$10 – $7,500

Darell BignerNCT05734560